Ho and colleagues (J Chromatogr A, 2012), developing doping-control assays, characterised a veterinary preparation sold as TB-500 that contained only the heptapeptide LKKTETQ, the actin-binding active site spanning residues 17 to 23 of T4
Brain Res Prot 7 : 1120 Garzya G, Corallo D, Fiore A, Lecciso G, Petrelli G, Zotti C
The evidence consistently indicates the potential of metformin as the anchor pharmacological agent drug across the entire GLP-1 RA care continuum, during therapy and beyond, when clinically indicated
UrWay serves patients across most U.S
Cholelithiasis A total of 4 trials were evaluated regarding the risk of cholelithiasis in patients receiving GLP-1 RAs
Record lot number, expiry, received quantity, treatment use, and remaining stock so purchasing and clinical documentation remain aligned